Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/42 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/099187SARS-COV-2 ANTIGEN-BINDING PROTEINS AND USES THEREOF
WO 12.05.2022
Int.Class A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
Appl.No PCT/US2021/058593 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor ABRAHAM, Jonathan
The present invention provides severe acute respiratory syndrome coronavirus (SARS-CoV), e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen- binding proteins, pharmaceutical compositions, and methods of use thereof to passively immunize and treat subjects having or at risk of having a SARS-CoV, e.g., SARS-CoV-2, infection.
2.20210353620Method of treating severe acute respiratory syndrome (SARS) virus infection by administering a protein disulfide isomerase (PDI) inhibitor
US 18.11.2021
Int.Class A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
Appl.No 17320069 Applicant The University of Vermont and State Agricultural College Inventor Vikas Anathy

Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.

3.20230357366Antigen Binding Molecules Targeting SARS-CoV-2
US 09.11.2023
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 18313306 Applicant Generate Biomedicines, Inc. Inventor Francesco Borriello

The disclosure provides, in various embodiments, polypeptides (e.g., antibodies and antigen binding fragments thereof) that specifically bind to S2 domains of betacoronavirus Spike glycoproteins, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoproteins. The disclosure also provides, in various embodiments, fusion proteins comprising one or more of polypeptides, polynucleotides encoding polypeptides, vectors and host cells suitable for expressing polypeptides, and methods for treating viral infections (e.g., COVID-19).

4.WO/2022/015573SARS-COV-2 ANTIGEN-BINDING PROTEINS AND USES THEREOF
WO 20.01.2022
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/US2021/040900 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor ABRAHAM, Jonathan
The present invention provides severe acute respiratory syndrome coronavirus (SARS-CoV), e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen-binding proteins and methods of use thereof to passively immunize and treat subjects having or at risk of having a SARS-CoV, e.g., SARS-CoV-2, infection.
5.WO/2021/206638VACCINE AND/OR ANTIBODY FOR VIRAL INFECTION
WO 14.10.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/SG2021/050197 Applicant INTRA-IMMUSG PRIVATE LIMITED Inventor ZENG, Qi
The present invention relates to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) N-protein and/or an immunogenic fragment thereof and uses thereof. The invention also includes a nucleic acid molecule encoding the SARS-CoV-2 N-protein and/or an immunogenic fragment thereof; and uses thereof. The SARS-CoV-2 N protein and/or immunogenic fragment thereof may be produced by recombinant DNA technology or may be chemically synthesised. In particular, the SARS-CoV-2 N-protein and/or an immunogenic fragment thereof and/or nucleic acid molecule encoding the SARS-CoV-2 N-protein and immunogenic may be for use as a vaccine. The invention further includes an antibody capable of binding to the SARS-CoV-2 N-protein or antigen-binding fragment thereof and uses thereof.
6.WO/2006/086561NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME-ASSOCIATED CORONAVIRUS
WO 17.08.2006
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/US2006/004599 Applicant NEW YORK BLOOD CENTER Inventor JIANG, Shibo
The present invention provides an isolated antibody capable of binding to the receptor- binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS- CoV S protein.
7.WO/2024/026553NOVEL ANTIGENIC EPITOPE AGAINST SARS-COV-2 AND USES THEREOF
WO 08.02.2024
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CA2022/051182 Applicant CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL Inventor FINZI, Andrés
The present application discloses antigenic peptides that are recognized by neutralizing anti-SARS-CoV-2 antibodies. Neutralizing antibodies targeting these antigenic peptides are effective against several SARS-CoV-2 variants. Conjugates, vesicles, pharmaceutical compositions and vaccines comprising the antigenic peptides, as well as antibodies recognizing these antigenic peptides, are also disclosed. The antigenic peptides and encoding nucleic acids, conjugates, antibodies or antigen-binding fragments thereof, vesicles, pharmaceutical compositions or vaccines described herein may be used for the prevention and/or treatment of coronavirus infection and/or associated diseases and symptoms, such as SARS-CoV-2 infection and/or COVID-19.
8.WO/2023/159316FORMULATION OF ANTI-SARS-COV-2 NEUTRALIZING ANTIBODIES AND USES THEREOF
WO 31.08.2023
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/CA2023/050235 Applicant IMMUNE BIOSOLUTIONS INC. Inventor FUGÈRE, Alexandre
The present application relates to a composition comprising a combination of anti-SARS- CoV-2 antibodies or antigen-binding fragments thereof, or of nucleic acids encoding the anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. Methods and uses of the compositions for the prevention and/or treatment of betacoronavirus infections and related diseases such as COVID-19, are also described. The compositions may be administered in the respiratory tract, e.g., in nebulized or aerosolized form, to subjects infected with or at risk of being infected with a coronavirus such as SARS-CoV-2.
9.WO/2021/228092NOVEL MONOCLONAL ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF
WO 18.11.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2021/093083 Applicant CHANG GUNG MEMORIAL HOSPITAL, LINKOU Inventor HUANG, Kuan-Ying
Provided are novel monoclonal antibodies or the antigen-binding fragments thereof, which bind to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or angiotensin-converting enzyme 2 (ACE2). Also provided are a pharmaceutical composition and a kit for detecting the presence of SARS-CoV-2 in a sample comprising the novel monoclonal antibody or the antigen-binding fragments thereof. Also disclosed herein are methods for detection or prevention and/or treatment of SARS-CoV-2 or a disease mediated by a disease mediated by ACE2.
10.WO/2021/257607TREATMENT FOR HUMAN CORONAVIRUS INFECTION
WO 23.12.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2021/037486 Applicant THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND Inventor BIX, Gregory Jaye
Treating a human coronavirus (hCoV) infection includes administering an effective amount of an inhibitor of an α5- or αv-containing integrin to a subject in need thereof. The integrin inhibitor can be ATN-161. The hCoV can be SARS-CoV or SARS-CoV-2.